Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NRX Pharmaceuticals Inc NRXP

Financial Services Healthcare
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of... see more

Recent & Breaking News (NDAQ:NRXP)

NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression

PR Newswire October 31, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

PR Newswire October 26, 2023

NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference

PR Newswire October 12, 2023

NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference

PR Newswire October 5, 2023

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

PR Newswire October 2, 2023

NRx Pharmaceuticals Publishes Shareholder Update Letter

PR Newswire September 20, 2023

NRx Pharmaceuticals to Present at the Sidoti Virtual Small Cap Conference

PR Newswire September 18, 2023

NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression

PR Newswire September 15, 2023

NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support

PR Newswire September 14, 2023

NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

PR Newswire September 7, 2023

NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens

PR Newswire September 6, 2023

NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain

PR Newswire August 30, 2023

NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share

PR Newswire August 29, 2023

SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Investors to Contact the Firm

Business Wire August 16, 2023

NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

PR Newswire August 14, 2023

NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023

PR Newswire August 7, 2023

NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101(TM) for Chronic Pain

PR Newswire August 7, 2023

NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire June 27, 2023

NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire June 23, 2023

NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

PR Newswire June 20, 2023